A Canadian perspective on the safe administration of bendamustine and the prevention and management of adverse events

J. Koolwine, T. Crosbie, G. Gazzé, R. Turner, J. Wiernikowski, W. Assaily


Although bendamustine has been used to treat lymphoproliferative disorders for decades, it has only recently been approved for use in Canada. Thus, Canadian recommendations on the administration of bendamustine and the management of common adverse events (aes) are needed. This article highlights effective management and assessment strategies recommended by Canadian nurses and pharmacists for the most common aes arising from the use of bendamustine in patients with chronic lymphocytic leukemia and indolent non-Hodgkin lymphoma. Those strategies include administering bendamustine over 60 minutes instead of 30 minutes, administering pre-medications to control infusion-related reactions and nausea, hydrating patients to minimize fatigue, and using free-flowing saline at the closest port to prevent phlebitis.


Bendamustine; adverse events; toxicities; chronic lymphocytic leukemia; indolent non-Hodgkin lymphoma; nhl; cll; inhl; fatigue; nausea

Full Text:

PDF HTML Corrigendum

DOI: http://dx.doi.org/10.3747/co.21.1855

Copyright © 2019 Multimed Inc.
ISSN: 1198-0052 (Print) ISSN: 1718-7729 (Online)